Neuberger Berman Group
VTGN icon

Neuberger Berman Group’s VistaGen Therapeutics VTGN Stock Holding History

Neuberger Berman Group’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,251
Closed -$8.42K – 1890
2023
Q1 		$8.42K Buy
+2,251
New +$11.8K ﹤0.01% 1790
2022
Q4 		– Sell
-1,887
Closed -$9K – 1881
2022
Q3 		$9K Buy
+1,887
New +$18.7K ﹤0.01% 1809

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Neuberger Berman Group's VTGN Position: Q2 2023 in Review

Neuberger Berman Group sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 2,251 shares — an estimated $8.42K sold.

Neuberger Berman Group first reported a position in VTGN in Q3 2022 and held it in 2 quarters. The position peaked at $9K in Q3 2022. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • Neuberger Berman Group reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Neuberger Berman Group sold 2,251 VistaGen Therapeutics shares in Q2 2023, an estimated $8.42K.
  • Neuberger Berman Group first reported a position in VistaGen Therapeutics in Q3 2022 and held it in 2 quarters.
  • Neuberger Berman Group's VistaGen Therapeutics position peaked at $9K in Q3 2022.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Neuberger Berman Group's 13F filing for Q2 2023, filed 11 Aug 2023.